deltatrials
Completed PHASE3 NCT00882518

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode

Sponsor: AstraZeneca

Conditions Schizophrenia
Interventions Chlorpromazine Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)
Updated 7 times since 2017 Last updated: Apr 16, 2012 Started: Apr 30, 2009 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

Listed as NCT00882518, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2009, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baoding, China, Beijing, China, Changsha, China, Guangzhou, China, Harbin, China, Hunan, China, Kunming, China, Nanjing, China, Shanghai, China, Wuhan, China and 1 more location